We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quidel (QDEL) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Quidel (QDEL - Free Report) closed at $113.95, marking a +1.29% move from the previous day. This move outpaced the S&P 500's daily gain of 1.12%. Meanwhile, the Dow gained 1.01%, and the Nasdaq, a tech-heavy index, lost 0.08%.
Prior to today's trading, shares of the medical diagnostics company had gained 8.51% over the past month. This has outpaced the Medical sector's gain of 7.36% and the S&P 500's gain of 4.63% in that time.
Quidel will be looking to display strength as it nears its next earnings release, which is expected to be May 4, 2022. On that day, Quidel is projected to report earnings of $9.28 per share, which would represent year-over-year growth of 111.87%.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $15.75 per share and revenue of $2 billion. These totals would mark changes of -11.12% and +17.67%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Quidel. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Quidel is currently a Zacks Rank #1 (Strong Buy).
Looking at its valuation, Quidel is holding a Forward P/E ratio of 7.14. This represents a discount compared to its industry's average Forward P/E of 23.1.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 158, putting it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Quidel (QDEL) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Quidel (QDEL - Free Report) closed at $113.95, marking a +1.29% move from the previous day. This move outpaced the S&P 500's daily gain of 1.12%. Meanwhile, the Dow gained 1.01%, and the Nasdaq, a tech-heavy index, lost 0.08%.
Prior to today's trading, shares of the medical diagnostics company had gained 8.51% over the past month. This has outpaced the Medical sector's gain of 7.36% and the S&P 500's gain of 4.63% in that time.
Quidel will be looking to display strength as it nears its next earnings release, which is expected to be May 4, 2022. On that day, Quidel is projected to report earnings of $9.28 per share, which would represent year-over-year growth of 111.87%.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $15.75 per share and revenue of $2 billion. These totals would mark changes of -11.12% and +17.67%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Quidel. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Quidel is currently a Zacks Rank #1 (Strong Buy).
Looking at its valuation, Quidel is holding a Forward P/E ratio of 7.14. This represents a discount compared to its industry's average Forward P/E of 23.1.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 158, putting it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.